Sales and Marketing

Showing 15 posts of 11527 posts found.

Pfizer secures expanded approval for Ibrance

April 3, 2017 Sales and Marketing Pfizer, ibrance

Pfizer has announced that FDA has approved its supplemental New Drug Application (sNDA) for Ibrance, meaning that the drug is …

FDA issues US-wide recall of Mylan’s EpiPen

April 3, 2017 Medical Communications, Sales and Marketing FDA, Mylan, epipen

After recent reports of around 80,000 defective EpiPen’s across Australia, New Zealand, Japan, Norway, Denmark, Finland and Ireland, the FDA …

Astellas lines up Ogeda for acquisition in $853 million deal

April 3, 2017 Sales and Marketing Astellas, Ogeda SA, menopause

Astellas, based in Tokyo, has announced that it has agreed a deal to acquire Belgium-based Ogeda SA. The deal will …

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

March 31, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing PCI services

Introduction More than three years have passed since the US federal government signed the Drug Supply Chain Security Act (DSCSA) …

Top Ten most popular articles on Pharmafile.com this week

March 31, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten

It’s the end of the week, and the headlines were populated with stand-out stories that proved popular with our readers. …

FDA approves first-ever atopic dermatitis biologic treatment

March 31, 2017 Medical Communications, Sales and Marketing Dupixent, Regeneron, Sanofi, atopic dermatitis, biologic

Sanofi and Regeneron’s Dupixent (dupilumab) has become the first biologic medicine to be approved by the FDA for the treatment …

AstraZeneca ends month with two pieces of news

March 31, 2017 Medical Communications, Sales and Marketing AstraZeneca, Tagrisso, TerSera Therapeutics, Zoladex

AstraZeneca has ended the month with more positive news on Tagrisso, that had previously been approved in China under its …

Takeda names new President of Europe and Canada Business Unit

March 31, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment

Takeda has named Giles Platford as its new President of Europe and Canada (EUCAN) Business Unit as of 1 April, …

Insider Interview: ABPI’s Paul Catchpole discusses NICE’s new fast-track appraisal system

March 30, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Insider Interview, NICE, Paul Catchpole, fast track

Paul Catchpole, Value and Access Director at the Association of the British Pharmaceutical Industry (ABPI), gives his thoughts on the …

Trump’s FDA pick vows to sever past pharma ties to avoid partisanship

March 30, 2017 Medical Communications, Sales and Marketing FDA, Scott Gottlieb, Trump

After much speculation, Donald Trump recently announced his top pick for Commissioner of the FDA as Dr Scott Gottlieb. Gottlieb …

Mylan’s generic of best-selling GSK drug delayed by FDA

March 30, 2017 Sales and Marketing Advair, GSK, Mylan

Mylan’s plan to bring its generic competitor to GSK’s best-selling respiratory drug, Advair, has hit a major snag after it …

First treatment for form of MS approved by FDA

March 30, 2017 Sales and Marketing Biogen, Genentech, MS, Roche

In big news for sufferers of MS and the company that developed the drug, Roche subsidiary Genetech, the FDA has …

Novartis investigational CAR-T therapy gets FDA priority review

March 30, 2017 Sales and Marketing CTL019, FDA, Novartis, leukaemia

Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy CTL019 (tisagenlecleucel-T) has been awarded has been awarded priority review by …

The April 2017 edition of Pharmafocus is available to read online now!

March 29, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, Pharmafocus new issue

From industry reaction to NICE’s new regulatory guidelines to the rising threat of counterfeit medicine, you can read all the …

Breakthrough eczema drug given FDA approval

March 29, 2017 Research and Development, Sales and Marketing Dupixent, Regeneron, Sanofi

Regeneron and Sanofi have received approval for its eczema treatment, Dupixent, by the FDA. The treatment will be the first …
The Gateway to Local Adoption Series

Latest content